| Online-Ressource |
Verfasst von: | Uliassi, Elisa [VerfasserIn]  |
| Krauth-Siegel, Renate [VerfasserIn]  |
Titel: | Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity |
Verf.angabe: | Elisa Uliassi, Giulia Fiorani, R. Luise Krauth-Siegel, Christian Bergamini, Romana Fato, Giulia Bianchini, J. Carlos Menéndez, Maria Teresa Molina, Eulogio López-Montero, Federico Falchi, Andrea Cavalli, Sheraz Gul, Maria Kuzikov, Bernhard Ellinger, Gesa Witt, Carolina B. Moraes, Lucio H. Freitas-Junior, Chiara Borsari, Maria Paola Costi, Maria Laura Bolognesi |
E-Jahr: | 2017 |
Jahr: | 3 October 2017 |
Umfang: | 11 S. |
Fussnoten: | Gesehen am 01.10.2018 |
Titel Quelle: | Enthalten in: European journal of medicinal chemistry |
Ort Quelle: | Amsterdam [u.a.] : Elsevier Science, 1987 |
Jahr Quelle: | 2017 |
Band/Heft Quelle: | 141(2017), Seite 138-148 |
ISSN Quelle: | 1768-3254 |
Abstract: | Crassiflorone is a natural product with anti-mycobacterial and anti-gonorrhoeal properties, isolated from the stem bark of the African ebony tree Diospyros crassiflora. We noticed that its pentacyclic core possesses structural resemblance to the quinone-coumarin hybrid 3, which we reported to exhibit a dual-targeted inhibitory profile towards Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR). Following this basic idea, we synthesized a small library of crassiflorone derivatives 15-23 and investigated their potential as anti-trypanosomatid agents. 19 is the only compound of the series showing a balanced dual profile at 10 μM (% inhibitionTbGAPDH = 64% and % inhibitionTcTR = 65%). In phenotypic assay, the most active compounds were 18 and 21, which at 5 μM inhibited Tb bloodstream-form growth by 29% and 38%, respectively. Notably, all the newly synthesized compounds at 10 μM did not affect viability and the status of mitochondria in human A549 and 786-O cell lines, respectively. However, further optimization that addresses metabolic liabilities including solubility, as well as cytochromes P450 (CYP1A2, CYP2C9, CYP2C19, and CYP2D6) inhibition, is required before this class of natural product-derived compounds can be further progressed. |
DOI: | doi:10.1016/j.ejmech.2017.10.005 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: http://dx.doi.org/10.1016/j.ejmech.2017.10.005 |
| Volltext: http://www.sciencedirect.com/science/article/pii/S0223523417307973 |
| DOI: https://doi.org/10.1016/j.ejmech.2017.10.005 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Coumarins |
| Crassiflorone |
| Glyceraldehyde-3-phosphate dehydrogenase |
| Leishmaniasis |
| Natural products |
| Quinones |
| Trypanocidal activity |
| Trypanosomiasis |
| Trypanothione reductase |
K10plus-PPN: | 1581457626 |
Verknüpfungen: | → Zeitschrift |
Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity / Uliassi, Elisa [VerfasserIn]; 3 October 2017 (Online-Ressource)